LeMaitre Vascular (LMAT) Stock Overview
Develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
LMAT passed our risk checks.
LMAT Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
LeMaitre Vascular, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$86.61 |
| 52 Week High | US$109.58 |
| 52 Week Low | US$71.42 |
| Beta | 0.77 |
| 1 Month Change | -1.41% |
| 3 Month Change | 2.67% |
| 1 Year Change | -8.72% |
| 3 Year Change | 93.24% |
| 5 Year Change | 142.67% |
| Change since IPO | 1,296.94% |
Recent News & Updates
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
Oct 26
LeMaitre Vascular: Investment Debate Remains In Place
Sep 16Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
Aug 30LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Aug 06Recent updates
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
Oct 26LeMaitre Vascular: Investment Debate Remains In Place
Sep 16Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
Aug 30LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Aug 06Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Jul 18Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Jun 18Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Apr 24Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Apr 12LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Mar 31LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 11Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Mar 02When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Feb 04We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
Jan 22LeMaitre Vascular: Losing Steam
Jan 15A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Jan 09LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Dec 22LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
Nov 24LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Nov 03LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 02Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
Oct 08Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
Sep 17
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
Sep 04If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
Aug 22LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Jul 23Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Jul 12Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Jun 18Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
Jun 05LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
May 02Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
Apr 04Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Feb 29What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jan 19Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture
Oct 27Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Oct 11Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?
Aug 30The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence
Jul 06Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?
May 20Shareholder Returns
| LMAT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.9% | -2.9% | 0.5% |
| 1Y | -8.7% | -0.8% | 20.1% |
Return vs Industry: LMAT underperformed the US Medical Equipment industry which returned -0.8% over the past year.
Return vs Market: LMAT underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| LMAT volatility | |
|---|---|
| LMAT Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LMAT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LMAT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 658 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
| LMAT fundamental statistics | |
|---|---|
| Market cap | US$1.96b |
| Earnings (TTM) | US$47.12m |
| Revenue (TTM) | US$234.64m |
Is LMAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMAT income statement (TTM) | |
|---|---|
| Revenue | US$234.64m |
| Cost of Revenue | US$72.48m |
| Gross Profit | US$162.16m |
| Other Expenses | US$115.05m |
| Earnings | US$47.12m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | 2.08 |
| Gross Margin | 69.11% |
| Net Profit Margin | 20.08% |
| Debt/Equity Ratio | 46.4% |
How did LMAT perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 03:37 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LeMaitre Vascular, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |